Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune
Ahmet Arac1, Sara E Brownell, Jonathan B Rothbard
1Department of Neurosurgery, Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford Stroke Center, Stanford University School of Medicine, Stanford, CA 94305, USA.
Abstract:
Tissue plasminogen activator is the only treatment option for stroke victims; however, it has to be administered within 4.5 h after symptom onset, making its use very limited. This report describes a unique target for effective treatment of stroke, even 12 h after onset, by the administration of αB-crystallin (Cryab), an endogenous immunomodulatory neuroprotectant. In Cryab(-/-) mice, there was increased lesion size and diminished neurologic function after stroke compared with wild-type mice. Increased plasma Cryab was detected after experimental stroke in mice and after stroke in human patients. Administration of Cryab even 12 h after experimental stroke reduced both stroke volume and inflammatory cytokines associated with stroke pathology. Cryab is an endogenous anti-inflammatory and neuroprotectant molecule produced after stroke, whose beneficial properties can be augmented when administered therapeutically after stroke.
